Clinical Trial Update: A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 pilot trial evaluating the combination of trientine and vemurafenib for BRAF-mutated metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• SYPRINE (trientine hydrochloride)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Duke University | Conditions: Melanoma | Phase 1 | Status: WITHDRAWN